Zou He-de, Zhang Pei-Hai, Chen Wen-Kang, Hu Bao-Feng, Wang Jian-Wei, Zeng Hong-Sen, Du Guan-Chao, Gao Qing-He, Ma Zi-Yang, Ma Yong-Jie, Zhang Ya-Peng, Cao Rui, Zhang He-Kun, Lin Wei, Xu Hao-Ran, Zhao Jia-You
Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, 100700, China.
Department of Andrology, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, 100091, China.
Chin J Integr Med. 2025 Sep 12. doi: 10.1007/s11655-025-4142-0.
To evaluate the effect and safety of Chinese herbal compound Huashi Tongbi Formula (HTF) for the treatment of erectile dysfunction (ED) with damp heat affecting Pi (Spleen) pattern, and explore the possible mechanisms based on the analysis of gut microbiota.
In this multicentre, randomized, parallel, positive control, noninferiority trial, a total of 162 ED patients with damp heat affecting Pi pattern were randomly divided into a treatment group (108 patients) and a control group (54 patients) in a 2:1 ratio using a random number table method. The treatment group was administered HTF granules (1 bag each time, twice a day). The control group was given sildenafil citrate tablets (50 mg, orally as needed). Both groups were treated for 8 weeks with a 8-week followed-up period. The main indicator was effective rate after 8-week treatment analysed using intention-to-treat (ITT) and per-protocol (PP) methods, and the secondary indicators included International Index of Erectile Function-5 (IIEF-5) score, Erectile Quality Score (EQS), and Chinese medicine syndrome (CMS) score, which were analysed using ITT every 2 weeks during 8-week treatment period, and every 4 weeks during 8-week follow-up period. The 16S rDNA sequencing was used to analyse the impact of HTF on the gut microbiota. The adverse events (AEs) and changes in safety indicators of the two groups were recorded.
A total of 162 patients were included in the ITT analysis, with 23 patients dropping out during the trial period (12 in the treatment group and 11 in the control group), and 139 patients were included in the PP analysis. ITT and PP analyses revealed that after 8-week treatment the difference and 95% confidence intervals (CIs) in the effective rates between the treatment and the control groups were -3.7% (-17.9%, 10.5%) and -4.5% (-18.2%, 9.2%), respectively. At 2 weeks of treatment, the treatment group showed lower IIEF-5 and EQS scores but higher CMS score vs. control (P<0.05); at 4 weeks, IIEF-5 remained lower (P<0.05), while EQS and CMS scores were comparable (P>0.05); by 6 weeks, all scores (IIEF-5, EQS, CMS) were similar between groups (P>0.05); at 8 weeks, IIEF-5 and EQS were comparable, but CMS scores were lower (P<0.05). During 4- and 8-week follow-up, the treatment group had higher IIEF-5 and EQS scores and lower CMS scores (P<0.05). Both groups showed significant improvements in all scores from baseline (P<0.05). There was no significant difference in the safety indicators between groups (P>0.05). After HTF treatment, the relative abundances of Lachnospiraceae and Blautia increased, contributing the most to the differences in the microbial communities between groups. The abundances of Levilactobacillus and Lactiplantibacillus increased, whereas the abundances of Bilophila, Saccharimonadia, Patescibacteria, and others decreased in the treatment group (linear discriminant analysis score>2). Nine predictive functions of the gut microbiota including amino acid related enzymes, exosome, mitochondrial biogenesis, etc. were reduced, whereas protein kinase function increased in the treatment group (P<0.05).
HTF showed noninferior efficacy to sildenafil for ED with damp heat affecting Pi pattern, with the advantages of relieving overall symptoms and stable and lasting therapeutic effect after discontinuation, potentially mediated by gut microbiota modulation. (Registration No. ChiCTR2300067825).
评价中药复方化湿通痹方(HTF)治疗湿热蕴脾型勃起功能障碍(ED)的疗效和安全性,并基于肠道微生物群分析探索其可能机制。
在这项多中心、随机、平行、阳性对照、非劣效性试验中,采用随机数字表法将162例湿热蕴脾型ED患者按2∶1比例随机分为治疗组(108例)和对照组(54例)。治疗组给予HTF颗粒剂(每次1袋,每日2次)。对照组给予枸橼酸西地那非片(50mg,按需口服)。两组均治疗8周,随访8周。主要指标为治疗8周后的有效率,采用意向性分析(ITT)和符合方案分析(PP)方法;次要指标包括国际勃起功能指数-5(IIEF-5)评分、勃起质量评分(EQS)和中医证候(CMS)评分,在治疗8周期间每2周、随访8周期间每4周采用ITT方法进行分析。采用16S rDNA测序分析HTF对肠道微生物群的影响。记录两组的不良事件(AE)和安全性指标变化。
ITT分析共纳入162例患者,试验期间23例患者脱落(治疗组12例,对照组11例),PP分析纳入139例患者。ITT和PP分析显示,治疗8周后,治疗组与对照组有效率的差值及95%置信区间(CI)分别为-3.7%(-17.9%,10.5%)和-4.5%(-18.2%,9.2%)。治疗2周时,治疗组IIEF-5和EQS评分低于对照组,CMS评分高于对照组(P<0.05);4周时,IIEF-5仍较低(P<0.05),而EQS和CMS评分相当(P>0.05);6周时,两组所有评分(IIEF-5、EQS、CMS)均相似(P>0.05);8周时,IIEF-5和EQS相当,但CMS评分较低(P<0.05)。在4周和8周随访期间,治疗组IIEF-5和EQS评分较高,CMS评分较低(P<0.05)。两组所有评分较基线均有显著改善(P<0.05)。两组安全性指标差异无统计学意义(P>0.05)。HTF治疗后,毛螺菌科和布劳特氏菌属的相对丰度增加,对两组微生物群落差异贡献最大。治疗组中左旋乳酸杆菌属和植物乳杆菌属的丰度增加,但嗜胆菌属、糖单孢菌属、Patescibacteria等的丰度降低(线性判别分析得分>2)。治疗组肠道微生物群的9种预测功能包括氨基酸相关酶、外泌体、线粒体生物发生等降低,而蛋白激酶功能增加(P<0.